Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Upstream's New Sinus Treatment Cuts Need For Surgery, Early Trial Finds

Pipette,Adding,Fluid,To,One,Of,Several,Test,Tubes,,Medical

The medical landscape for chronic rhinosinusitis is rapidly advancing, with new treatments offering hope for improved quality of life for patients. As pharmaceutical companies race to develop effective therapies, recent clinical trials are shedding light on promising solutions.

Upstream Bio Inc. (NASDAQ:UPB) on Tuesday shared topline results from the Phase 2 VIBRANT trial evaluating verekitug in participants with chronic rhinosinusitis with nasal polyps (CRSwNP).

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.